Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
Rule 144 notice: The filer proposes to sell 3,731 shares of common stock of Jazz Pharmaceuticals (JAZZ) with an aggregate market value of $417,872.00. The proposed trades are to occur on NASDAQ with an approximate sale date of 08/08/2025. The securities were acquired the prior day, 08/07/2025, through restricted stock vesting from the issuer and the stated nature of payment is compensation.
The notice reports nothing to report for securities sold during the past three months. The filer affirms, by signing the form, they do not possess undisclosed material adverse information about the issuer. This filing is a routine Rule 144 disclosure describing an intended sale of newly vested shares under standard resale procedures.
Jazz Pharmaceuticals reported a Form 144 notice showing an insider intends to sell 3,731 shares of common stock on NASDAQ through ETRADE, with an aggregate market value of $417,872 and total shares outstanding reported as 60,658,809. The shares were acquired by restricted stock vesting on 08/07/2025 and the proposed sale date is listed as 08/08/2025. The filing states payment was for compensation and notes no securities sold in the past three months. The filer also certifies they are not aware of any undisclosed material adverse information.
Jazz Pharmaceuticals submitted a Form 144 reporting a proposed sale of 3,731 common shares on NASDAQ through ETRADE FINANCIAL CORPORATION, with an aggregate market value of $417,872.00. The shares were acquired via restricted stock vesting on 08/07/2025 and the approximate date of sale is listed as 08/08/2025. The filing lists 60,658,809 shares outstanding, so the proposed sale represents a very small fraction of the company’s equity. The record shows Nothing to Report for securities sold in the past three months and lists the nature of payment as COMPENSATION. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Jazz Pharmaceuticals (JAZZ) filed a Form 144 disclosing a proposed Rule 144 sale of 3,731 shares of common stock with an aggregate market value of $417,872. The notice lists the broker as ETRADE FINANCIAL CORPORATION and an approximate sale date of 08/08/2025 on NASDAQ. The securities were acquired on 08/07/2025 by restricted stock vesting from the issuer and were issued as compensation, with payment dated 08/07/2025. The issuer's total shares outstanding are reported as 60,658,809. The filer reports no securities sold in the past three months and attests they do not possess undisclosed material adverse information.
Form 4 highlight: On 08/05/2025 Jazz Pharmaceuticals (JAZZ) EVP & Chief Commercial Officer Samantha Pearce reported the disposition of 577 ordinary shares at $116.10 via code “F,” indicating shares were automatically withheld to satisfy tax obligations tied to the vesting of previously granted RSUs.
After this withholding, Pearce directly owns 40,815 ordinary shares. No derivative securities were exercised, and no open-market purchases or sales occurred. A footnote notes Pearce acquired 166 shares through the company’s Section 423 ESPP on 05/30/2025; these are already included in the current ownership total.
The transaction represents roughly 1.4 % of Pearce’s reported holdings and is routine, suggesting minimal signaling value. Investors may view the filing as neutral, with insider alignment largely unchanged.
Quarter ended June 30, 2025: Jazz Pharmaceuticals reported total revenues of $1,045,712 for Q2 2025 (product sales $985,571; royalties/contract $60,141), up modestly versus Q2 2024. Operating loss was $686,392 for the quarter, driven primarily by a $905,362 acquired in‑process R&D expense related to the April 21, 2025 Chimerix acquisition. Net loss for the quarter was ($718,470) (basic EPS ($11.74)).
Balance sheet and cash flow: Cash and cash equivalents declined to $1,189,880 from $2,412,864 at 12/31/2024, reflecting the Chimerix purchase (total cash consideration $944.2M) and other investing/financing uses. Total debt outstanding was $5,364,094 with the current portion increasing to $1,028,478 (2026 Notes included). Total shareholders' equity fell to $3,706,359. Net cash provided by operating activities for six months was $518,639; net cash used in investing was $809,951; financing used $937,991.
Other material items: Goodwill rose to $1,843,974; finite‑lived intangible assets net $4,768,987; five customers represented 81% of gross accounts receivable (ESSDS 41%). Foreign currency translation produced a quarter FX gain of $299,790 to other comprehensive income.
Jazz Pharmaceuticals (JAZZ) has filed a Form 144 indicating that Chairman & CEO Bruce C. Cozadd intends to sell up to 9,000 common shares through Merrill Lynch on or about 1 Aug 2025. Based on the reference price in the filing, the sale is valued at approximately $1.10 million, equal to ~0.01% of the company’s 61.6 million shares outstanding.
The shares were acquired via equity-compensation grants made between December 2021 and February 2022. Over the past three months Cozadd has already sold 2,500 shares for gross proceeds of $276.6 k. The filer certifies under Rule 144 that he possesses no undisclosed material adverse information.
While such sales are common for liquidity or tax purposes, investors often view continued insider selling—especially by the CEO—as a potential signal of tempered confidence. Market watchers may track any additional Form 4 filings or 10b5-1 plan disclosures for context.